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Gene delivery to, and gene targeting in, stem cells would
be a highly enabling technology for basic science and
biomedical application. Adeno-associated viral (AAV)
vectors have demonstrated the capacity for efficient
delivery to numerous cells, but their application to stem
cells has been limited by low transduction efficiency.
Due to their considerable advantages, however, engineering AAV delivery systems to enhance gene delivery
to stem cells may have an impact in stem cell biology
and therapy. Therefore, using several diverse AAV capsid
libraries—including randomly mutagenized, DNA shuffled, and random peptide insertion variants—we applied
directed evolution to create a “designer” AAV vector with
enhanced delivery efficiency for neural stem cells (NSCs).
A novel AAV variant, carrying an insertion of a selected
peptide sequence on the surface of the threefold spike
within the heparin-binding site, emerged from this evolution. Importantly, this evolved AAV variant mediated
efficient gene delivery to rat, mouse, and human NSCs,
as well as efficient gene targeting within adult NSCs, and
it is thus promising for applications ranging from basic
stem cell biology to clinical translation.
Received 14 August 2010; accepted 26 November 2010; published online
11 January 2011. doi:10.1038/mt.2010.287

Introduction
Stem cells—defined by the hallmark properties of self-renewal,
i.e., the capacity to expand, maintain themselves in an undifferentiated state, as well as differentiation into one or more specialized lineages—have considerable biomedical potential. However,
better approaches must be developed to control their behavior.
Gene delivery can serve as a valuable tool for numerous applications, including modulating stem cell fates by up-/downregulating specific genes, developing stem cell–based models of
human disease, and tracking of stem cells or their progeny upon
implantation in vivo.1–2

Current methods to mediate gene delivery to stem cells include
plasmid- and viral vector-mediated delivery. Plasmid-based gene
transfer offers typically transient gene expression and a large carrying capacity;3 however, current plasmid delivery systems for stem
cells can suffer from low transfection efficiency.4 Alternatively,
viral vectors based on retroviruses and lentiviruses offer high
infectivity and stable gene expression and have been extensively
employed in stem cell studies for genetic marking, protein or
RNA overexpression, and targeted knock-down of endogenous
gene expression.5,6 However, in some cases transient expression
is desirable, such as for the temporary overexpression of regulatory signals to manipulate stem cells.7–9 Furthermore, insertional
mutagenesis is a concern for potential downstream clinical application of retroviruses.10 Adenoviral vectors also have potential
for efficient delivery and transient gene expression in stem cells,11
though the most commonly used adenoviral vectors carry numerous virally-encoded factors that may perturb cell function.12 An
efficient vector that mediates transient gene expression in stem
cells may therefore have utility in the field.
In addition to gene delivery, the capacity for gene targeting via
homologous recombination at specific loci in a mammalian stem
cell genome has many potential applications, including basic investigation of processes of organismal development and mechanisms
of human disease, the targeted introduction of genetic material
into a genome without insertional mutagenesis, and therapeutic
gene correction.13 However, plasmid-mediated gene targeting is
typically very inefficient. Recent approaches that use zinc finger
nucleases to enhance gene targeting efficiencies are highly promising, though they require engineering a new zinc finger nuclease
for each new locus one would like to manipulate.14,15
Adeno-associated virus (AAV) is a parvovirus with a 4.7 kb
single-stranded DNA genome containing two genes (rep and
cap), and vectors based on AAV have proven safe and effective
for clinical application.16–18 Exposure to AAV results in persistent,
latent infection in a broad range of both dividing and nondividing
cells.19,20 Additionally, Russell and colleagues have demonstrated
that AAV vector genomes can mediate homologous recombination
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Results
AAV library generation
We found that several wild-type AAV serotypes (2, 4, 5, 6, and 8)
exhibited low transduction efficiencies [0.7–9.7% with multiplicity of infection (MOI) 105] of NSCs (Figure 1a), as previously
described.24,25 These results motivated pursuing directed evolution for the development of novel AAV variants that can more
effectively infect NSCs. Three large (>106 independent clones
each), diverse libraries were used: (i) random viral chimeras created via pairwise DNA shuffling of the AAV2 cap gene with that
of AAV4, 5, 6, or 8, (ii) AAV2 capsid variants with a random 7
amino acid sequence inserted into a key loop region,32 and (iii)
random point mutants of the cap gene of AAV2 generated via
error prone PCR18 (Figure 1b). Libraries were packaged as previously described to generate a large pool of AAV mutant capsids
containing the genome encoding those mutants.18 NSCs, isolated
from the hippocampus of adult Fisher 344 rats,27 were infected by
each AAV library, adenovirus serotype 5 was added to induce the
replication and rescue of the “successful” AAV variants, the surviving AAV cap genes were recovered by PCR and cloned into the
AAV genome plasmid, and the next generation library was packaged. After four such iterative selection steps, the resulting viral
pool was subjected to additional mutagenesis by error prone PCR
on the selected cap genes, followed by further iterative selections
668

(Figure 1b). During the three rounds of evolution and 10 selection steps, the variant pool became progressively more infectious
than wild-type AAV2 (data not shown).

AAV variants selected through directed evolution
DNA sequencing analysis revealed that the final pools contained seven AAV variants: two shuffled, three peptide-inserted,
and two error prone clones (Figure 2, Table S1). Interestingly,
the shuffled clones (r3.1, r3.10) were composed of AAV2 and
AAV5 sequences, with additional point mutations located on
the viral surface. Although AAV2 and 5 were less efficient than
AAV4 and AAV6 (Figure 1a), the low efficiencies of AAV4 and
AAV6 [<10% green fluorescent protein positive (GFP+) NSCs
at a MOI 105] may be insufficient to enable wild-type cap4 and
cap6 to be represented in the selected pool. Furthermore, combinations of fragments of cap4 and cap6 with cap2 likely yield
gene delivery properties that are distinct from the parental cap
4 and cap6. In addition, two peptide insertions were present in
three clones (r3.3, r3.21, r3.45), which also carried several point
mutations.

a
Percentage of GFP+ cells

with target sequences in a cellular genome at efficiencies 103–104fold higher than plasmid constructs.21 This capability has been
successfully applied to cells that AAV can effectively transduce,
including fibroblasts and recently mesenchymal stem cells, which
has led to the development of new animal models of human disease.22,23 Although AAV-mediated gene expression and targeting
would be effective tools for stem cell studies, AAV vectors are
unfortunately extremely inefficient for gene delivery numerous
stem cell types.24,25 Therefore, the development of new AAV variants capable of efficient stem cell infection may have impact in
stem cell biology and regenerative medicine.
Embryonic neural stem cells (NSCs) are centrally involved
in the development of the nervous system,26 and adult NSCs
play a fundamental role in learning and memory and may yield
new therapies for neurodegenerative disorders.27 However, AAV
is extremely inefficient on NSCs.25 Our recent work highlights
the potential of directed evolution to create new viruses with
enhanced gene delivery properties.18,28–31 In this approach, we generate large (~107) and highly diverse libraries of viral variants, and
the application of an evolutionary pressure—such as the ability to
infect a stem cell—selects for the “fittest” variants. Importantly,
this general approach can yield successful variants in the absence
of mechanistic knowledge of which step(s) in the viral entry pathway—such as cell surface binding, intracellular trafficking, and/or
nuclear entry—pose(s) the most substantial barrier to infection.
In this study, we have applied directed evolution to create a novel
AAV vector with the capacity for high efficiency gene delivery
to adult rat NSCs, and this variant was also efficient in murine
and human NSCs. Furthermore, this high delivery efficiency was
applied to enhance gene correction frequencies in NSCs, potentially providing a tool with potentially strong utility for both basic
biology and biomedical application.

20

15

10

5

0

b

AAV2

AAV4

AAV5

AAV6

AAV8

(1)
Shuffled

Peptide
insertion

EP/StEP
(2)

AAV2-AAV4
AAV2-AAV5
AAV2-AAV6
AAV2-AAV8

(7)
(3)
(4)

(5), (6)

(8)

(9)

(10)

Figure 1 Rationale and strategy for engineering novel AAV variants.
(a) Rat neural stem cell (NSC) infection with wild-type adeno-associated
viral (AAV) 2, 4, 5, 6, and 8. Cells were infected by addition of green fluorescent protein (GFP) vectors at a multiplicity of infection (MOI) of 105.
Cells were incubated with virus for 24 hours, followed by analysis of GFP
expression by flow cytometry after an additional 24 hours. Even at this
high MOI, the highest gene delivery efficiency was <10%. (b) Directed
evolution of novel AAV vectors for enhanced NSC infection: (1) plasmid
libraries were generated by DNA shuffling, peptide insertion, and error
prone PCR [error prone (EP)], (2) viral libraries were packaged, (3) NSCs
were infected with libraries, followed by adenovirus addition, (4) the
resulting amplified AAV variants were harvested, and (5) viral genomes
were isolated and cloned. The cycle of steps (2)–(5) was iterated (7) with
(6) additional EP PCR after the fourth and seventh cycles. Newly evolved
clones were used to produce recombinant virus (8) and analyzed for the
ability to infect NSCs (9), and the final clone was selected (10).
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Figure 2 Schematic maps of novel adeno-associated viral (AAV) variants. AAV r3.1 denotes the first AAV clone isolated after three rounds of
evolution. The gray and blue coloring depicts AAV2 capsid and AAV5 capsid regions, respectively. In the peptide-inserted vectors, “LA” and “A” were
inserted as linkers.

Novel AAV variant with enhanced properties
for NSC infection
These capsid mutants were used to package recombinant vector encoding GFP driven by a cytomegalovirus (CMV) promoter, which revealed that six of the variants exhibited similar
or slightly improved efficiencies compared to AAV2 or AAV5
(Supplementary Figure S1). Additional rounds of selection
would likely have eliminated these variants to yield a dominant clone.30 In stark contrast, however, the variant AAV r3.45
mediated high delivery efficiencies (Figure 3a–f). At MOI of
103, 104, and 105, AAV r3.45 infected 14.4–50 fold more cells
relative to AAV2 and AAV5 (Figure 3d–f). Importantly, 7 days
after infection with AAV r3.45, nearly 100% of GFP+ cells
maintained expression of the neural progenitor marker nestin (Figure 4a), indicating that infected cells remained in an
immature state.
AAV r3.45 carried an insertion of LATQVGQKTA (where LA
and A are linker residues) at amino acid 587 with an additional
V719M mutation (Figure 4b). The inserted peptide likely lies on
the surface of the threefold spike within the heparin-binding site
(Figure 4c,d), and the point mutation is also surface-exposed.
AAV r3.3, which harbored the same peptide insertion but with
three different point mutations (i.e., V118I, S537C, and G599S),
exhibited considerably lower packaging titers and infectivities
than AAVr3.45, indicating that slight capsid modifications can significantly impact viral properties (Figure 1 and Supplementary
Figure S1). Importantly, AAV r3.45 was additionally highly
infectious for both murine and human NSCs (Figure 5a–c).
It was also infectious in several other nonpermissive cell types
(Supplementary Figure S2), though not in human or murine
embryonic stem cells (Supplementary Figure S3a,b), indicating
that its benefits are somewhat cell selective. However, despite its
lack of cell specificity, its enhanced gene delivery to cultured NSCs
from three different species met the goals of this study and indicates that AAV r3.45 may be used in a variety of stem cell applications, such as transient expression of factors or gene targeting to
generate knock-ins/-outs for basic investigation or the development of disease models.
Molecular Therapy vol. 19 no. 4 apr. 2011

To investigate the roles of the peptide insertion and the
V719M mutation for the enhancement of NSC infection, the
V719M mutation was reversed via site-directed mutagenesis,
and the resulting variant, which contains the peptide insertion
without the V719 mutation, was packaged and employed to infect
NSCs. This correction of the V719M mutation did not influence the infectivity, indicating the peptide sequence displayed
on the AAV r3.45 capsid is critical to enhance gene delivery to
NSCs (Supplementary Figure S4). However, although a BLAST
search (http://www.ncbi.nlm.nih.gov/BLAST/) revealed that
the inserted sequence bears sequence similarity to a number of
intracellular enzymes (e.g., Halobacterium salinarum naphthoate
synthase), it was not similar to any secreted mammalian or viral
capsid proteins.
To determine whether this variant may still use heparan
sulfate as its primary receptor, despite its peptide insertion
within the AAV2 heparin-binding domain,33 we compared
the heparin affinity of AAV r3.45 to that of wild-type AAV2.
Purified AAV2 or AAV r3.45 was loaded onto a heparin column and eluted with a series of increasing NaCl concentration (150–750 mmol/l, and 1 mol/l), and a portion of each
fraction was added to 293T cells to quantify infectious virus
(Supplementary Figure S5). Similar to previous reports,18,29
fractions from 450 to 550 mmol/l NaCl contained the majority
of wild-type AAV2. However, AAV r3.45 eluted in a sharp peak
between 350 mmol/l and 450 mmol/l, indicating that heparan
sulfate may still be primary receptor, but its affinity to heparan
sulfate may be slightly altered.

Enhanced gene correction frequency
with newly designed AAV variant
We next assessed the capacity of AAV r3.45 to mediate gene
correction in NSCs. GFP cDNA harboring a stop codon (mutGFP1) was introduced into adult rat NSCs using a lentiviral
vector. In parallel, a promoter-less GFP with a distinct stop
codon (mutGFP2) was packaged into a recombinant AAV vector (Figure 6), and the resulting gene targeting construct carrying mutGFP2 had 586 nucleotides of homology upstream and
669
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Figure 3 Neural stem cell (NSC) transduction by adeno-associated virus (AAV) r3.45. (a) Phase-contrast microscopy and (b) fluorescence microscopy of cells infected by AAV r3.45 [genomic multiplicity of infection (MOI): 105] shows a high level of transduction. Bar = 100 µm. (c) Histogram of
green fluorescent protein (GFP)-expressing cells: MOI 103 (red), MOI 104 (green), MOI 105 (blue). Efficiencies of recombinant AAV2, AAV5, and AAV
r3.45 were quantified by flow cytometry at (d) MOI 103, (e) 104, and (f) 105.
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Figure 4 Neural stem cells (NSCs) infected with adeno-associated virus (AAV) r3.45 remain undifferentiated. (a) Seven days after infection with
AAV r3.45, immunostaining revealed that the majority of green fluorescent protein expressing cells were positive for nestin, a neural progenitor cell
marker. Bar = 20 µm. (b) Schematic representation of the peptide sequence, point mutation, and heparin-binding residues of AAV clone r3.45. (c)
Structural model of a VP3 subunit of AAV r3.45, as well as (d) the full capsid. The color scheme for panels b–d is: V719M (blue), peptide sequence at
amino acid 587 (red), and heparin-binding residues (R585/R598) (purple).
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Figure 5 Enhanced neural stem cell tropism of AAV r3.45. Comparison of transduction efficiencies of adeno-associated virus (AAV) r3.45 versus
AAV2 for (a) murine neural stem cells (NSCs), (b) human fetal NSCs, and (c) human neural progenitor cells. Cells were infected at a multiplicity of
infection (MOI) of 103, 104, and 105, and green fluorescent protein (GFP) expression was analyzed via flow cytometry 48 hours after infection.

1,548 nucleotides downstream of the amber mutation in mutGFP1. Upon infection of NSC-mutGFP1 cells with the targeting vector, recombination with the integrated lentiviral vector
corrected the amber mutation in mutGFP1, resulting in fluorescent NSCs (Figure 7a). Importantly, AAV r3.45 demonstrated
a significantly improved capacity (six- to tenfold) to repair the
670

single-base pair mutation in NSC-mutGFP1 cell line compared
to AAV2 and AAV5 (Figure 7b, Table S2). Controls, including the infection of NSC-mutGFP1 cell lines by AAV CMV Luc
(Figure 7c) and naive NSCs infected by the targeting vectors
(data not shown), did not yield GFP expression, verifying the
specificity of the process.
www.moleculartherapy.org vol. 19 no. 4 apr. 2011
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Verification of gene correction
To confirm the GFP gene correction, GFP+ cells were isolated by
fluorescence-activated cell sorting 14 days after AAV infection,
and cellular genomic DNA was subjected to PCR to amplify the
GFP sequence specifically from the lentiviral vector. Sequence
analysis of 24 cloned PCR fragments revealed 19 corrected
TAC

Bam HI

LTR

UB

eGFP

TAA

DISCUSSION
AAV is a highly versatile vector with a broad-host range; however, its delivery efficiency to certain cell types, including neural or embryonic stem cells, is low.24,25 One potential reason is a
lack of necessary cell surface receptors for a given serotype (e.g.,
heparan sulfate, integrins), resulting in low attachment affinity
and cellular internalization. Alternatively, intracellular trafficking
pathways can also pose barriers, as for example nuclear trafficking
of AAV is a key rate-limiting step for AAV transduction of some
cell types such as murine fibroblasts.34 Additionally, noncapsid
related limitations including double-stranded DNA synthesis can
compromise AAV-mediated gene expression.35 Our finding that
a short peptide insertion into the exterior surface of AAV2 can
substantially increase delivery efficiency implicates capsid-related
steps such as receptor binding or intracellular trafficking as potential barriers.
The slight shift in the heparin affinity of this variant AAV
r3.45 (Supplementary Figure S5) may correspond to a significant

Xho I

IRES PuroR

LTR

603

Bam HI
16

sequences (79.2%), with the five uncorrected sequences presumably resulting from NSCs infected with multiple lentiviral vectors
(Figure 7d,e). In parallel, sorted cells were expanded for an additional 26 days (total 40 days after AAV infection), and ~94.5% of
cells maintained GFP and nestin expression (Figure 8).

Lentiviral vector-mutGFP1
(target site)
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eGFP
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GAG TAG
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eGFP
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Corrected sequence
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Figure 6 Schematic representation of a lentiviral vector carrying
UB-mutGFP1-IRES-PuroR, the adeno-associated viral (AAV)-mutGFP2
targeting vector, AAV cytomegalovirus (CMV) promoter Luc, and the
corrected sequence at the target site. Genetic elements include: the
ubiquitin promoter (UB), internal ribosome entry site (IRES), puromycin
acetyltransferase (PuroR), mutGFP1 [a single-base substitution (C → A)
603 nucleotides (nt) from the 5′ end of green fluorescent protein (GFP)],
and mutGFP2 [a single point mutation (G → T) 16 nt into GFP]. eGFP,
enhanced green fluorescent protein; LTR, long terminal repeat.
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Figure 7 Adeno-associated virus (AAV) r3.45-mediated gene correction by homologous recombination with a nonfunctional green fluorescent protein (GFP) expressed in neural stem cells (NSC) and verification of gene correction. (a) Immunostaining of GFP+, gene-corrected NSCmutGFP1 cells 72-hours postinfection with the AAV-mutGFP2 targeting vectors: GFP (green), DAPI (blue). Example images with a lower (top row) and
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Molecular Therapy vol. 19 no. 4 apr. 2011

671

© The American Society of Gene & Cell Therapy

An Evolved AAV Variant With Enhanced Neural Stem Cell Tropism

a

b
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Figure 8 Maintenance of the undifferentiated state of gene-corrected, green fluorescent protein (GFP)-expressing neural stem cells 35-days
postinfection. (Nestin: red, GFP: green). The nuclei of cells were co-stained with TOPRO3 (blue). Bar = 50 µm. (a–c: ×200, d–f: ×50, a,d: GFP, b,e:
nestin/TOPRO, c,f: GFP/nestin/TOPRO3).

modulation of heparan sulfate binding, potentially due to the
inserted peptides’ conformational alteration of a key exposed loop
of the heparin binding domain. However, the fact that the majority of AAV r3.45 still eluted at relatively high NaCl concentrations
indicates that this variant may still utilize heparan sulfate as its
primary receptor. In addition, the LATQVGQKTA peptide may
thus contribute to binding to an alternate secondary receptor or
to an intracellular transduction step. Future studies may elucidate
this mechanism of action.
The central goal of the directed evolution in this study was to
create novel vectors that can better infect NSCs; therefore, positive selection was applied for enhanced adult rat NSC transduction, and negative selection was not applied to remove tropism
for other cell types. The approach successfully yielded a novel
AAV variant with significantly enhanced infectivity of not only
adult rat but also mouse and two human NSCs. As anticipated this
enhanced infectivity was not accompanied by specificity for NSCs,
as AAV r3.45 was more efficient than AAV2 for several cell types,
including primary human astrocytes (Supplementary Figure S2).
Accordingly, in vivo AAV r3.45 would be anticipated to transduce
NSCs as well as other surrounding cell types (i.e., astrocytes, oliogodendrocytes). However, alternative selection strategies could
be implemented to achieve specificity of delivery.
The development of an efficient vehicle for transient gene
expression in neural stem cells has applications ranging from the
overexpression of factors to induce the differentiation or “programming” of neural stem cells, as well as potentially expression
of defined transcription factors to reprogram cells.36,37 Moreover,
enhanced transduction and gene targeting capabilities in NSCs
may facilitate stem cell biology and regenerative medicine
672

investigations, potentially including the introduction of defined
mutations for basic studies, generation of reporter cell lines, and
therapeutic gene correction. By yielding a variant with high efficiency gene delivery and gene targeting in NSCs, directed evolution is further established as a powerful approach to engineer
novel capabilities into AAV vectors.18,28–31 Further reverse engineering analysis of the gene delivery mechanisms of this variant
may elucidate mechanisms that limit gene delivery in stem cells,
as well as the other cell types efficiently infected by this variant.
Finally, this general approach may in the future be applied to
other cell and stem cell types, thereby extending the utility of
AAV to additional biotechnology and biomedical applications.

Materials and Methods
NSC culture. Adult rat NSCs, isolated from the hippocampal region of
6-week-old female Fisher 344 rats as described,27,38 were cultured on tissue
culture polystyrene dishes previously coated with poly-ornithine (10 µg/ml)
(Sigma-Aldrich, St Louis, MO) and mouse laminin (5 µg/ml) (Invitrogen,
Carlsbad, CA), in Dulbecco’s modified Eagle’s medium (DMEM)/F-12
(1:1) (Invitrogen) containing N-2 supplement (Invitrogen) and 20 ng/ml
of recombinant human fibroblast growth factor 2 (Peprotech, Rocky Hill,
NJ). Under these conditions, nearly 100% of cells express nestin and Sox2
(data not shown). Every 2–3 days (>60% confluency), cells were split into
a fresh dish by mechanical dissociation using polished pasteur pipettes.
Adult murine NSCs (a kind gift of Prof Andrew Wurmser, University of
California at Berkeley) were cultured in DMEM with 20 ng/ml of recombinant fibroblast growth factor 2 (Peprotech) and 8 μg/ml of heparin.
Human fetal NSCs (13 weeks of gestational age) were derived from the
telencephalon (HFT13) as previously described39 and were cultured in
DMEM/F-12 containing N-2 supplement, 20 ng/ml of fibroblast growth
factor 2, 8 μg/ml of heparin (Sigma-Aldrich), and 10 ng/ml of leukemiainhibitory factor (Chemicon, Temecula, CA). Human neural progenitor
www.moleculartherapy.org vol. 19 no. 4 apr. 2011
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cells were derived from a variant of the human embryonic stem cell line
BG01 (BresaGen, Athens, GA), BG01V2, using the stromal derived inducing activity involving a co-culture system of human embryonic stem cells
and mouse stromal cell line PA6 (Riken BioResource Center Cell Bank,
Tsukuba, Japan) (Vazin et al. manuscript in preparation) and were cultured in DMEM/F-12 supplemented with N-2, 20 ng/ml basic fibroblast
growth factor, 20 ng/ml epidermal growth factor (Invitrogen), and 50 U/
ml Penicillin/Streptomycin.
Plasmid library construction. Random mutagenesis libraries were

generated by subjecting cap genes from AAV2 to error prone PCR as
previously described.18 Peptide display libraries were generated similar to previous reports.32,40 Briefly, a unique Avr II was introduced into
pSub2Cap2 between amino acid 587 and 588 by PCR mutagenesis. A
random 21 base pair oligonucleotide [5′-GGAGGGCTAGCA (NNK)7
GCTAGCAAAAGCGGGGGGAGAGTGAGG-3′] was annealed to an
antisense primer 5′-CCTCACTCTCCCCCCGCT-3′, followed by synthesis of the second strand. The resulting dsDNA inserts were digested with
Nhe I and ligated into the unique Avr II site of pSub2Cap2. Pairwise DNA
shuffling libraries of AAV2 with AAV4, AAV5, AAV6, or AAV8 (AAV2AAV4, AAV2-AAV5, AAV2-AAV6, and AAV2-AAV8) were generated
by PCR amplification of cap genes from AAV2, AAV4, AAV5, AAV6,
and AAV8 and followed by insertion into pSub2. Each viral gene was
then amplified via PCR, and DNA shuffling was performed as previously
described.41,42 Briefly, DNase I digestion of equimolar amounts of PCRamplified cap genes yielded fragments ranging from 50 to 500 base pair in
size. Fragments were gel purified and reassembled without primers in the
following conditions: 96 °C, 3 minutes; 40 cycles of 94 °C, 55 °C, and 72 °C;
and 72 °C, 10 minutes. Assembled fragments were further amplified by
PCR and cloned into pSub2 for replication competent AAV production.
Selection of viral libraries. The plasmid library was used to package rep-

lication competent AAV as previously described,18,43 and the resulting
viral libraries were then harvested as described.44 Virus was purified using
OptiPrep (60%, wt/vol iodixanol) (Sigma-Aldrich) density gradient ultracentrifugation according to the manufacturer’s instructions, and genomic
titers of AAV viral libraries were determined by quantitative real time
PCR on a Bio-Rad iCycler (Bio-Rad, Hercules, CA) using a Taqman probe
(Biosearch Technologies, Novato, CA).18
NSCs, seeded at a density of 6 × 105 per well in 6-well tissue culture
plates coated with poly-ornithine/laminin one day prior to infection, were
infected with either wild-type AAV2 or the AAV libraries at genomic MOIs
of 10, 100, and 1,000. After a 24-hour exposure, cells were co-infected with
adenovirus serotype 5 in fresh medium (i.e., DMEM/F12 + N2, fibroblast
growth factor 2). Once cells exhibited cytopathic effect, after approximately
two additional days of culture, they were lysed by three freeze/thaw steps,
followed by the treatment with benzonase (1 unit/ml) (Sigma-Aldrich)
at 37 °C for 30 minutes. Adenovirus was inactivated by incubating the
viral lysates at 50 °C for 30 minutes. To quantify viral libraries rescued
from the each selection, viral genomic DNA was extracted from DNaseresistant particles. At each step, the total viral genomic DNA rescued was
compared for the viral libraries versus wild-type AAV2.
Evolution of viral libraries. One round of evolution is defined as cap mutagenesis followed by several selection steps, i.e., NSC infection and adenovirus
rescue. After 3–4 selection steps, the rescued AAV cap genes were randomly
mutated by error prone PCR as previously described.18 The resulting PCR
products were digested with Hind III and Not I, and the fragments were ligated
into pSub2 to create a new replication competent AAV plasmid library with
at least 106 independent clones. Viral library packaging was then conducted
by the calcium phosphate transient transfection method,18 and viral titration
and purification were performed as with the initial library construction.
After the evolution was completed, AAV cap genes were extracted
from the final pool of successful AAV variants, and genomic sequences
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were analyzed at the UC Berkeley DNA Sequencing Facility. The extracted
viral genomes were amplified by PCR and inserted into the pXX2 Not
I recombinant AAV (rAAV) packaging plasmid.22,33. Three-dimensional
models of the VP3 subunit were generated using Swiss Model (http://
swissmodel.expasy.org) with the coordinates of AAV2 (Protein Databank
accession no. 1LP3) supplied as template, and images were rendered in
Pymol (http://pymol.sourceforge.net/) and Rasmol.
Heparin column chromatography. AAV r3.45 and AAV2 binding to heparin were analyzed as previously described.18,29 Briefly, ~1011 purified genomic
particles of virus were loaded onto a 1 ml HiTrap heparin column (GE
Healthcare Life Sciences, Pittsburgh, PA), which was previously equilibrated
with Tris buffer (50 mmol/l, pH 7.5) containing 150 mmol/l NaCl. Elutions
were performed with 0.75 ml of Tris buffer containing increasing increments
of 50 mmol/l NaCl up to 750 mmol/l, followed by a 1 mol/l NaCl wash. Small
fractions (75 μl) of each elution were added to 2.5 × 105 293T cells cultured in
12-well dishes and employed to quantify the level of infectious virus present.
Forty-eight hour postinfection, GFP expression was measured with Becton
Dickinson fluorescence-activated cell sorting Caliber (Yonsei University
College of Medicine Medical Research Center, Seoul, Korea).
NSC transduction. To test the infectivity of rAAV cap clones, vectors carrying cDNA encoding GFP were packaged using the transient transfection
method. Briefly, an equal mass (17 µg) of three plasmids—a AAV helper
plasmid (carrying a cap variant), CMV GFP vector plasmid containing
ITR (pAAV CMV GFP SN), and pHelper plasmid—were transfected via
calcium phosphate into AAV293 cells,18,27 and viral vectors were harvested
and purified as described above. Genomic titers of each rAAV vector were
determined by quantitative PCR.
One day prior to AAV infection, NSCs were plated onto 24-well
dishes at a density of 30,000 cells/well. On day 1, cells were infected by
the rAAV clones at genomic MOIs (103, 104, and 105) and incubated for
additional 48 hours before analysis. The resulting transduction efficiencies
of the individual rAAV variants on rat and murine NSCs were quantified
with a Beckman–Coulter EPICS XL flow cytometer (UC Berkeley Cancer
Center, Berkeley, CA) and compared to those of AAV2 and AAV5, which
were chosen as controls since the two shuffled clones that emerged from
the evolution carried fragments from AAV cap2 and AAV cap5 (Figure 1).
Human NSC and neural progenitor cell transduction efficiencies were
quantified with a Becton Dickinson fluorescence-activated cell sorting
Caliber (Yonsei University College of Medicine Medical Research Center)
and Beckman–Coulter FC 500 flow cytometer (Berkeley Stem Cell Center,
Berkeley, CA), respectively.
Immunofluorescence staining. To analyze AAV r3.45 infection of undifferentiated NSCs, and the effects of AAV infection on NSC differentiation,
immunostaining for nestin (undifferentiated NSCs), β-III-tubulin (neurons), and glial fibrillary acidic protein (astrocytes) was conducted.31 NSCs
were seeded onto 8-well chamber slides and infected as indicated above.
At 48 hours postinfection, cells were fixed in 4% paraformaldehyde for 15
minutes and blocked with 5% goat serum in 0.3% Triton X-100/phosphatebuffered solution for 30 minutes at room temperature. Cells were incubated overnight at 4 °C with primary antibodies. For nestin/β-III-tubulin
co-staining, rabbit anti-rat nestin (1:500 dilution; Abcam) and mouse
anti-β-III-tubulin (1:500 dilution; Sigma-Aldrich), and, for nestin/glial
fibrillary acidic protein costaining, mouse anti-rat nestin (1:1,000 dilution;
BD Biosciences) and guinea-pig anti-glial fibrillary acidic protein(1:1,000
dilution; Advanced ImmunoChemical, Long Beach, CA) were used.
Subsequently, cells were rinsed thoroughly and stained with secondary fluorescent-conjugated antibodies, including goat anti-rabbit Alexa 546 (1:250
dilution; Molecular Probes, Carlsbad, CA), goat anti-mouse Cy5 (1:250
dilution; Jackson ImmunoResearch, West Grove, PA), goat anti-mouse Cy3
(1:250 dilution; Jackson ImmunoResearch), or goat anti-guinea-pig Cy5
(1:250 dilution; Jackson ImmunoResearch). Stained cells were imaged by
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fluorescence confocal microscopy (Leica Microsystems, Bannockburn, IL)
or fluorescence microscopy (Nikon ECLIPSE TE2000-E, Nikon, Melville,
NY, or Olympus IX50, Olympus America). When amplifying GFP signals,
rabbit anti-GFP (1:2,000 dilution; Invitrogen, Center Valley, PA) and goat
anti-rabbit Alexa 488 (1:250 dilution; Invitrogen) were used as primary and
secondary antibodies, respectively.
Generation of mutant GFP NSC line. An internal ribosome entry site and

puromycin resistance gene cassette was cloned into the Eco RI and Xho I
sites of pFUGW (a kind gift from David Baltimore, California Institute of
Technology, Pasadena, CA), which contains an enhanced GFP gene under
the control of human ubiquitin-C promoter.45 To insert an amber stop
codon (TAA) into the GFP sequence, the substitution of “C” to “A” was
introduced 603 nucleotides from the 5′ end of GFP via QuikChange sitedirected mutagenesis. The inserted point mutation was verified by DNA
sequencing analysis.
A stable NSC cell population expressing the amber mutant GFP (NSCmutGFP1) was generated by infection with lentiviral vector carrying the
defective GFP. Briefly, 10 µg of pFUG carrying UB-mutGFP1-internal
ribosome entry site and puromycin resistance gene cassette, 5 µg of pMDL
g/p PRE, 3.5 µg of pcDNA3 IVS vesicular stomatitis virus G, and 1.5 µg of
pRSV Rev, were transfected into HEK 293T cell lines (>70% confluency)
by the calcium/phosphate transient transfection method.46 The lentiviral
vector was harvested and concentrated by ultracentrifugation (L8-55M
Ultracentrifuge; Beckman–Coulter, Brea, CA), followed by resuspension
in 100 µl of phosphate-buffered solution with 20% sucrose. Infectious
titer, determined as previously described,47 was 1.58 × 107 ± 4.66 × 106 IU/
ml. NSCs were seeded onto 6-well tissue culture plates at a density of 3 ×
105 cells/well and infected by 0, 1, 3, 5, 10, or 20 μl of the lentiviral vector.
After puromycin selection,48 the well in which 70–80% of cells survived
was expanded for further analysis. The integration of lentiviral genomes
was verified by cellular genomic DNA extraction, PCR amplification, and
sequencing analysis of the PCR products. Importantly, GFP fluorescence
was not detected in the mutGFP1 NSC cells, as confirmed by both flow
cytometry and immunostaining against GFP.
Gene targeting assay. A point mutation (G to T) was inserted 16 nucle-

otides from the 5′ end of GFP to yield a defective GFP open reading frame
(mutGFP2). Subsequently, pFUG was digested with Bam HI and Xho I,
and the mutGFP2-internal ribosome entry site and puromycin resistance
gene cassette was subcloned into an AAV vector plasmid (i.e., pAAV CMV
GFP SN), where CMV GFP was excised by Bam HI and Xho I, such that
the resulting targeting vector lacked a promoter. This genetic construct was
packaged into the AAV2, AAV5, and AAV r3.45 capsids, and AAV r3.45
carrying luciferase driven by CMV promoter was used as a negative control. All viral vectors were harvested and purified as described earlier.
NSCs were seeded onto 24-well tissue culture plates at a density of
50,000 cells/well 1 day prior to AAV infection. Each AAV targeting vector
was added to the NSCs at a genomic MOI of 5 × 105, and the medium was
replaced 24 hours later. Infected NSCs were analyzed by flow cytometry
(Cytomics FC500; Beckman–Coulter) 3 days after infection, and the
percentage of GFP+ cells was scored as the gene targeting frequency.
Cell sorting and sequencing. Cells continuously cultured for 14 days

after AAV r3.45 infection were sorted with a Cytopeia Influx Sorter (UC
Berkeley Cancer Center, Valencia, CA) to isolate FL1 (i.e., GFP) positive
cells. A fraction of the sorted cells was used for DNA sequencing analysis,
and the remainder was expanded for an additional 26 days, at which time
94.5% still expressed GFP (data not shown). For DNA sequencing analysis, cellular genomic DNA was extracted with the QIAamp DNA Micro Kit
(Qiagen) and amplified by using 5′-GCGGCAAGAACCCAAGGTCT-3′
and 5′-CGGCTTCGGCCAGTAACGTT-3′ primers. To specifically
amplify a fragment from the lentiviral vector and exclude amplification
from the AAV viral genome, the forward primer was designed to amplify
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from the half part of UB promoter in the targeted site, which existed only
in the lentiviral vectors. The resulting PCR products were cloned using
the StrataClone PCR cloning kit (Stratagene, La Jolla, CA), and individual
clones were sequenced to confirm the gene correction.

SUPPLEMENTARY MATERIAL
Figure S1. Percentages of GFP positive neural stem cells transduced
by recombinant vectors pseudotyped with capsids from AAV2, AAV5,
and selected AAV variants.
Figure S2. Comparison of transduction efficiencies of selected AAV
variants with wtAAV2 on a panel of cell types.
Figure S3. Comparison of transduction efficiencies of AAV r3.45
versus AAV2.
Figure S4. Comparison of transduction efficiencies of original AAV
r3.45 (peptide insertion + V719M point mutation) versus modified
AAV r3.45 (peptide insertion only, V719M correction).
Figure S5. Heparin column chromatograms for wild-type AAV2 and
AAV r3.45 to investigate the heparin affinity of AAV r3.45.
Table S1. Genomic and infectious titers of wild-type AAV serotypes
and AAV variants. Infectious titers were obtained from HEK 293T cell
infection.
Table S2. Genomic titers of gene targeting vectors.
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